HR810 is a new, very broad-spectrum cephalosporin with significant activity against members of the family Enterobacteriaceae, pseudomonads, gram-positive cocci, and anaerobes that is generally greater than the thirdgeneration cephalosporins (99.6% of 4,128 clinical facultative enteric isolates were inhibited by 58.0 ,ug of HR810 per ml). Tests and statistical methods to establish in vitro antimicrobial susceptibility test criteria favor tentative breakpoints of >18 mm (s8.0 ,ug/ml) as susceptible and <14 mm (232 ,ug/ml) as resistant. This provides a 93.7 to 98.3% absolute interpretive accuracy. Several preliminary ranges for zone sizes obtained with quality control organisms are proposed for the 30-,ug HR810 disk diffusion test used during the clinical trials. (3, 4, 9, 10, (13) (14) (15) . Its reported antimicrobial spectrum includes virtually all gram-negative bacilli, Staphylococcus spp., Streptococcus spp., Neisseria spp., and Haemophilus influenzae. It also has moderate or marginal activity against anaerobes, enterococci, and methicillin-resistant Staphylococcus aureus (3, 4, 9, 10, (13) (14) (15) . In this report we expand an earlier study (9) QC study. The third phase was a disk diffusion quality control (QC) evaluation. The study design and applied statistical methods have been reported before (1, 5). Participants in this phase included A. L. Barry, S. Brown (Good
tentative breakpoints of >18 mm (s8.0 ,ug/ml) as susceptible and <14 mm (232 ,ug/ml) as resistant. This provides a 93.7 to 98.3% absolute interpretive accuracy. Several preliminary ranges for zone sizes obtained with quality control organisms are proposed for the 30-,ug HR810 disk diffusion test used during the clinical trials.
HR810 or 1-[[(6R,7R) -7-[2-amino -4-thiazolyl)-glyoxyl-
amido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-en-3-yl] methyl]-6,7-dihydro-5H-cyclopenta-[blpyridinium hydroxide, 7-(Z)-(O-methyl-oxim) sulfate is a new 3' pyridium-substrated cefotaxime-like cephalosporin (3, 4, 9, 10, (13) (14) (15) . Its reported antimicrobial spectrum includes virtually all gram-negative bacilli, Staphylococcus spp., Streptococcus spp., Neisseria spp., and Haemophilus influenzae. It also has moderate or marginal activity against anaerobes, enterococci, and methicillin-resistant Staphylococcus aureus (3, 4, 9, 10, (13) (14) (15) . In this report we expand an earlier study (9) (11) . In the first phase of the study, each clinical laboratory tested HR810, ceftazidime, and cefotaxime (at 0.12, 0.5, 1.0., 2.0, 4.0, 8.0, and 32 p.gIml). In the diskregression evaluations, HR810 was tested in two-fold dilu-tions ranging from 256 to 0.0005 ,ug/ml, diluted in cationsupplemented Mueller-Hinton broth, and then dispensed (Prepared Media Laboratory, Tualatin, Oreg.) into microdilutioh trays along with dilutions ot other control drugs, cefotaxime and ceftazidime. Disk diftusion tests were performed by the method of Batter et al. (2) Table 3 of reference 12. consecutive clinical isolates in four clinical microbiology laboratories. The cumulative percentage of members of the Enterobacteriaceae inhibited at .;.0 ,ug/ml was 99.6%, a finding very similar to that reported earlier with a stock culture collection (9) . These data are significantly better than the two comparison drugs, ceftazidime and cefotaxime, used in this phase of the study (data not shown). Only 18
Enterobacteriaceae strains from Enterobacter cloacae, Escherichia coli, Morganella morganii, Proteus mirabilis, Providercia stuartii, and Serratia marcescens were HR810-resistant (MICs of .32 ,ug/ml). Nine of the isolates were Enterobacter cloacae, with a prevalence of 2.5% HT810 resistance compared to 14.1% for ceftazidime and 16.5% for cefotaxime. HR81O MICs against the Pseudomonas aeruginosa isolates (50% MIC [MIC50], 4.0 p,g/ml; MIC90, 32 p.g/ q,l) were most comparable to those reported for cefoperazone (6, 7, 9, 14) and sliglttly higher than those published for ceftazidime (7, 9, 14) and aztreonam (9) . The majority of Pseqdomonas spp. that were not Pseudomonas aeruginosa were also susceptible (MIC50, 2.0 ,ug/mI) to HR810, except Pseudomon,as maltophilia. HR810 was comparable to firstgeneration cephalosporins against Staphylococcus spp. (3, 9, 10, 13, 14) and was the most potent cephalosporin tested by our group against all Streptococcus spp. (3, 9, 13, 14) .
The HR810 activity against the enterococci (MIC50, 8.0 ,ug/ml) and methicillin-resistant Staphylococcus aureus (MIC50, 16 p.g/ml) would contribute to susceptibility test interpretive errors if these organisms are routinely tested against these cephalosporins (3, 9, 13, 14) . An unexpected findipg was the 55% of Streptococcus haemolyticus coagulase-negative strains that had resistant HRS1O MICs (>8.0 ,uglml).
The disk QC evaluation produced the results shown in Table 2 . Cefotaxime was used as an internal control of procedures, and zones obtained were compared to established NCCLS guidelines. The HR810 disk zones from the nine contributing laboratories suggest several QC guidelines, depending on the statistical analysis employed. The mean + two standard deviations could not be strictly applied to all data because the HR810 zones were abnormally distributed for the Pseudomonas aeruginosa QC strain tested. Vol. 20, 1984 I p bounding technique also was slightly compromised; however, this method establishes a Zs = .21 mm (all data) or Zs = .18 mm (excluding methicillin-resistant staphylococci and enterococcal strains) by using a susceptible MIC breakpoint of .8.0 ,ug/ml. If the latter zone was utilized with a 3-mm intermediate category (resistant, l14 mm) the interpretive errors would be 0.0% very major (false susceptible), 1.4% major (false resistant), and 4.9% minor errors. By lowering each breakpoint by 1 mm, the rates become 0.0% very major, 1.0% major, and 5.3% minor errors, or a 94.7% absolute agreement. When the methicillin-resistant staphylococci and enterococcal strains are eliminated from the analysis, the error rates are markedly reduced to 0.0% combined major and very major and 2.1% minor errors for the >17-mm and l13-mm criteria and 0.0% very major, 0.2% major, and 1.5% minor errors for the >18-mm and l14-mm criteria. The absolute agreement for these data (98.7%) favors the use of .18 mm as susceptible and .14 mm as resistant, a result very similar to that reported for other cephalosporins and similar new ,-lactams (7, 12) .
In summary, we presented information concerning the HR810 antimicrobial susceptibility testing from clinical microbiology labor4tories, including preliminary recommendation for in vitro disk and dilution testing and the QC of the disk diffusion method. We confirm that HR810 is an outstanding new ,B-lactam possessing a very wide spectrum of activity and particularly high potency against gram-positive cocci and nonenteric gram-negative bacilli (3, 4, 6-10, 13). We recommend tentative MIC breakpoints for standardized in vitro antimicrobial susceptibility tests (11, 12) of .8.0 ,ug/ ml (-18 mm) as susceptible and -32 ,ug/ml (.14 mm) as resistant.
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